Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMELIORATE: early intensification based on peripheral blast clearance in FLT3-mutated AML
2023-505901-17-00Phase 3Authorised
- Sponsor
- GIMEMA
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of midostaurin, cytarabine and daunorubicin in acute myeloid leukemia (AML) (2 arms), sponsored by GIMEMA. Primary endpoint: Event-free survival at 2 years. Planned start Apr 2020; status: authorised.
02
Drugs
midostaurincytarabinedaunorubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2023-505901-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505901-17-00.